Areplivir, included in the guidelines of the Ministry of Health of Russia for the treatment of COVID-19, received marketing authorization in Uzbekistan.

On August 4, 2021, Areplivir (favipiravir), a drug developed by Promomed and manufactured at the Biokhimik plant (part of the Promomed Group), was granted marketing authorization in the Republic of Uzbekistan.

Areplivir has a direct antiviral effect. Based on the results of clinical trials conducted in 2020 in five medical institutions in Russia under the guidance of members of the Russian Academy of Sciences, this drug has proven its high efficacy and safety, preventing the progression of coronavirus infection to a severe form. Today Areplivir is recommended by the Ministry of Health of Russia for the treatment of COVID-19 of any severity.

In September 2020, Promomed Group was one of the first in Russia to receive a permanent marketing authorization for a drug against the SARS-COV-2 virus, which made it possible to use the drug in outpatient settings. Almost immediately, Areplivir was included in the guidelines of the Ministry of Health of Russia for the prevention and treatment of COVID-19, and by the order of the Government of the Russian Federation from 21.10.2020 it was included in the list of vital and essential medicines (VED).

Compliance of the Biokhimik production complex with the requirements of the Good Manufacturing Practice of the Eurasian Economic Union, which is confirmed by the GMP certificate, will allow the Promomed Group to provide stable supplies of Areplivir in the territory of the Republic of Uzbekistan.

Maxim Smagin, General Director of the Promomed Group, said:

Approval of Areplivir, which is recommended by the Ministry of Health of the Russian Federation for the treatment of COVID-19, in Uzbekistan is an important step for us. I am proud that we can contribute to the fight against the pandemic not only on the territory of our country, but also to help neighboring states.